ATE421502T1 - Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen - Google Patents

Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen

Info

Publication number
ATE421502T1
ATE421502T1 AT01981242T AT01981242T ATE421502T1 AT E421502 T1 ATE421502 T1 AT E421502T1 AT 01981242 T AT01981242 T AT 01981242T AT 01981242 T AT01981242 T AT 01981242T AT E421502 T1 ATE421502 T1 AT E421502T1
Authority
AT
Austria
Prior art keywords
pain
treatment
type calcium
calcium channel
channel antagonists
Prior art date
Application number
AT01981242T
Other languages
English (en)
Inventor
Marc Chapdelaine
Lucius Kemp
John Mccauley
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE421502T1 publication Critical patent/ATE421502T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01981242T 2000-11-06 2001-10-31 Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen ATE421502T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0004056A SE0004056D0 (sv) 2000-11-06 2000-11-06 N-type calcium channel antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
ATE421502T1 true ATE421502T1 (de) 2009-02-15

Family

ID=20281716

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01981242T ATE421502T1 (de) 2000-11-06 2001-10-31 Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen

Country Status (9)

Country Link
US (1) US6841680B2 (de)
EP (1) EP1339690B1 (de)
JP (1) JP2004513118A (de)
AT (1) ATE421502T1 (de)
AU (1) AU2002212897A1 (de)
DE (1) DE60137534D1 (de)
ES (1) ES2319259T3 (de)
SE (1) SE0004056D0 (de)
WO (1) WO2002036569A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862301B1 (fr) * 2003-11-17 2007-12-21 Aventis Pharma Sa Nouveau procede de preparation de quinoleines 3-fluorees
WO2006105670A1 (en) * 2005-04-08 2006-10-12 Neuromed Pharmaceuticals Ltd. Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain
EP2019676A2 (de) * 2006-05-11 2009-02-04 Neuromed Pharmaceuticals, Ltd. Verfahren zur erhöhung der bioverfügbarkeit von benzhydrylpiperazinhaltigen verbindungen
SG10201508766UA (en) 2010-10-29 2015-11-27 Clino Ltd Tau imaging probe
MX2013010306A (es) 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
DE102016125645A1 (de) * 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2114727C (en) * 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants

Also Published As

Publication number Publication date
WO2002036569A1 (en) 2002-05-10
US20040053965A1 (en) 2004-03-18
AU2002212897A1 (en) 2002-05-15
DE60137534D1 (de) 2009-03-12
SE0004056D0 (sv) 2000-11-06
JP2004513118A (ja) 2004-04-30
ES2319259T3 (es) 2009-05-06
US6841680B2 (en) 2005-01-11
EP1339690A1 (de) 2003-09-03
EP1339690B1 (de) 2009-01-21

Similar Documents

Publication Publication Date Title
ATE323693T1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60135732D1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
ATE250576T1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
DE60117977D1 (de) Vorrichtungen zur behandlung von harninkontinenz
ES2151599T3 (es) Acidos hidroxamicos substituidos con arilsulfonamido como inhibidores de matriz metaloproteinasas.
DE69941586D1 (de) Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen
SE9900100D0 (sv) New compounds
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
DE69917957D1 (de) Blockcopolymerzusammensetzung für die Modifikation von Asphalt, und Asphaltzusammensetzung enthaltend diese Blockcopolymerzusammensetzung
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
DE60101354T2 (de) Diorganopolysiloxan/Acrylat-Copolymer enthaltende Emulsionen zur Behandlung von Flächengebilden
DE60204232D1 (de) Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen
DE60139428D1 (de) Konjugiertes Dienkautschukgel, Kautschukzusammensetzungen die dieses enthalten und Verfahren zur Herstellung von konjugiertem Dienkautschuk
DE69913548D1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
EP0657942A3 (de) Lateraler Bipolartransistor.
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
ATE381938T1 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
SE0004054D0 (sv) N-type calcium channel antagonists for the treatment of pain
DE60139195D1 (de) Aktivierbare polymerzusammensetzung, und gegenstände, die diese nutzen
ATE421502T1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
ATE259791T1 (de) N-alkyl-ammonium-acetonitril-salze, methoden dazu und zusammensetzungen die diese enthalten
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties